H1 Approvals Seen For Russian, Novavax COVID-19 Vaccines In India
J&J, Pfizer Yet To Begin Local Trials
Executive Summary
Multiple COVID-19 vaccines, including from RDIF and Novavax, could get accelerated approvals in India in the first half of calendar 2021, expanding the range at the country’s disposal. J&J's vaccine is expected to follow although it still hasn’t begun local trials, while Pfizer has temporarily withdrawn an application.
You may also be interested in...
Of Patents And Production: Industry-White House Row Over Vaccine Exports Highlights Policy Divide
BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.
Supply Concerns As India Fast Tracks COVID-19 Vaccines Approved By Certain Regulators
In an unusual move prompted by an enormous second wave of infections, India is accelerating approvals for COVID-19 vaccines granted emergency use authorizations by other selected regulators or on the WHO’s emergency use list without a local bridging study. While this seems a prelude to permitting private sales, where will the supplies come from?
EMA To Advise On Tweaking COVID-19 Vaccines Due To New Variants
Concerns that new or future mutations of the novel coronavirus may reduce the protection offered by existing COVID-19 vaccines have prompted the European Medicines Agency to develop guidance to help vaccine manufacturers who are planning to alter to their products.